- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
- Why 4/10
- REVTORPYK is already FDA-approved and commercially available, so the primary binary catalyst has passed. The next hard catalyst is the sNDA decision for the PIK3CA mutant label expansion, but no PDUFA date has been confirmed, so it is not a dated near-term binary. As an approved, launching product at a single-product company, the impact score is 4.
Watch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
Price Chart
Executive Summary
REVTORPYK (gedatolisib) is Celcuity Inc.'s first and only FDA-approved drug, cleared on July 14, 2026 for HR+/HER2-, PIK3CA wild-type advanced breast cancer. It is a kinase inhibitor that blocks PI3K and mTOR pathways. The drug became commercially available on September 30, 2026, and early launch metrics from the Q3 2026 earnings call showed strong account adoption (78% of top 36 strategic accounts ordering) and broad insurance coverage (91% of covered lives). A supplemental NDA for the larger PIK3CA mutant patient population was submitted in August 2026, which could roughly double the addressable market. The stock has fallen from ~$103 pre-approval to $66.79, reflecting a 'sell the news' pattern and investor concerns about the costly launch phase with no product revenue yet. Analyst consensus remains strongly bullish with a mean $151.25 price target.
How It Works
REVTORPYK is a kinase inhibitor that blocks multiple signaling pathways (class I PI3K isoforms and mTOR complexes) that cancer cells use to grow and survive. It is taken as an intravenous infusion and is designed to shut down these growth signals more broadly than existing targeted therapies.
Trial Status
REVTORPYK was approved by the FDA on July 14, 2026 based on the Phase 3 VIKTORIA-1 trial (NCT05501886, n=701) in HR+/HER2-, PIK3CA wild-type advanced breast cancer. The trial is now active but not recruiting, with primary completion estimated June 2026. Updated results from the PIK3CA mutant cohort were presented at ESMO 2026, showing median progression-free survival of 21.5 months with the gedatolisib triplet versus 9.1 months with alpelisib plus fulvestrant in patients without liver metastases.
The Two-Sided Case
Upcoming Catalysts
- sNDA decision for PIK3CA mutant label expansion (no confirmed PDUFA date yet; if standard review, ~June 2027; if priority review, ~February 2027)
- First meaningful quarterly product revenue reporting (Q4 2026 earnings, expected early 2027)
- Commercial launch metrics and prescription uptake data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Celcuity Inc. 8-K CELC ·Originating report